Search in:

Advanced search

Clinical Pharmacology: Advances and Applications Volume 4, 2012 - Issue

Submit an article Journal homepage

Open access

124

Views

CrossRef citations to date

Altmetric

Review

Pazopanib for the treatment of soft-tissue sarcoma

Pierre Heudel1 Department of Medical Oncology, Leon Berard Center, Lyon, France

Philippe Cassier1 Department of Medical Oncology, Leon Berard Center, Lyon, France

Olfa Derbel1 Department of Medical Oncology, Leon Berard Center, Lyon, France

Armelle Dufresne1 Department of Medical Oncology, Leon Berard Center, Lyon, France

Pierre Meeus2 Department of Surgical Oncology, Leon Berard Center, Lyon, France

Philippe Thiesse3 Department of Radiology, Leon Berard Center, Lyon, France

Dominique Ranchère-Vince4 Department of Pathology, Leon Berard Center, Lyon, France

Jean Yves Blay1 Department of Medical Oncology, Leon Berard Center, Lyon, France

Isabelle Ray-Coquard1 Department of Medical Oncology, Leon Berard Center, Lyon, France;5 EAM 4128 Sante-Individu-Societe, Lyon University, Lyon, FranceCorrespondence[email protected]

show all

Pages 65-70 | Published online: 26 Oct 2012

Cite this article

Full Article
Figures & data
References
Citations
Metrics
Licensing
Reprints & Permissions
View PDF PDF

References

CasaliPGBlayJYSoft tissue sarcomas: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-upAnn Oncol201021Suppl 5v198v20320555081
PubMed Web of Science ®Google Scholar
BlayJYCassierPARay-CoquardISoft tissue sarcomas: are all soft tissue sarcomas treated with the same drugs?Eur J Cancer201147Suppl 3S385S38821944026
PubMed Web of Science ®Google Scholar
ItalianoAMathoulin-PelissierSCesneALTrends in survival for patients with metastatic soft-tissue sarcomaCancer201111751049105420945333
PubMed Web of Science ®Google Scholar
DuBoisSDemetriGMarkers of angiogenesis and clinical features in patients with sarcomaCancer2007109581381917265525
PubMed Web of Science ®Google Scholar
MakiRGD’AdamoDRKeohanMLPhase II study of sorafenib in patients with metastatic or recurrent sarcomasJ Clin Oncol200927193133314019451436
PubMed Web of Science ®Google Scholar
GeorgeSMerriamPMakiRGMulticenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomasJ Clin Oncol200927193154316019451429
PubMed Web of Science ®Google Scholar
HarrisPABoloorACheungMDiscovery of 5-([4-[[2, 3- dimethyl-2H-indazol-6-yl]methylamino]-2-pyrimidinyl]amino)- 2-methyl-benzenesulfonamide (Pazopanib), a novel and potent vascular endothelial growth factor receptor inhibitorJ Med Chem200851154632464018620382
PubMed Web of Science ®Google Scholar
KumarRKnickVBRudolphSKPharmacokinetic–pharmacodynamic correlation from mouse to human with pazopanib, a multikinase angiogenesis inhibitor with potent antitumor and antiangiogenic activityMol Cancer Ther2007672012202117620431
PubMed Web of Science ®Google Scholar
BukowskiRMPazopanib: a multikinase inhibitor with activity in advanced renal cell carcinomaExpert Rev Anticancer Ther201010563564520469994
PubMed Web of Science ®Google Scholar
HurwitzHIDowlatiASainiSPhase I trial of pazopanib in patients with advanced cancerClin Cancer Res200915124220422719509175
PubMed Web of Science ®Google Scholar
KeisnerSVShahSRPazopanib: the newest tyrosine kinase inhibitor for the treatment of advanced or metastatic renal cell carcinomaDrugs201171444345421395357
PubMed Web of Science ®Google Scholar
SleijferSRay-CoquardIPapaiZPazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043)J Clin Oncol200927193126313219451427
PubMed Web of Science ®Google Scholar
Van GlabbekeMVerweijJJudsonJNielsenOSProgression-free rate as the principal end-point for Phase II trials in soft-tissue sarcomasEur J Cancer200238454354911872347
PubMed Web of Science ®Google Scholar
van der GraafWTBlayJChawlaSPPazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trialLancet201237998291879188622595799
PubMed Web of Science ®Google Scholar
MonkBJMas LopezLZarbaJJPhase II, open-label study of pazopanib or lapatinib monotherapy compared with pazopanib plus lapatinib combination therapy in patients with advanced and recurrent cervical cancerJ Clin Oncol201028223562356920606083
PubMed Web of Science ®Google Scholar
NegrierSPerolDBahledaRA phase I study of pazopanib (P) combined with bevacizumab (B) in patients with metastatic renal cell carcinoma (mRCC) or other advanced refractory tumors [abstract]J Clin Oncol2012304614
Google Scholar
du BoisAVergoteIWimbergerPOpen-label feasibility study of pazopanib, carboplatin, and paclitaxel in women with newly diagnosed, untreated, gynaecologic tumours: a phase I/II trial of the AGO study groupBr J Cancer2012106462963222240783
PubMed Web of Science ®Google Scholar
XuCFReckBHXueZPazopanib-induced hyperbilirubinemia is associated with Gilbert’s syndrome UGT1A1 polymorphismBr J Cancer201010291371137720389299
PubMed Web of Science ®Google Scholar
ClarkMAFisherCJudsonIThomasJMSoft-tissue sarcomas in adultsN Engl J Med2005353770171116107623
PubMed Web of Science ®Google Scholar
MahmoodSTAgrestaSVigilCPhase II study of sunitinib malate, a multi-targeted tyrosine kinase inhibitor in patients with relapsed or refractory soft tissue sarcomas. Focus on 3 prevalent histologies: leiomyosarcoma, liposarcoma, and malignant fibrous histiocytomaInt J Cancer12102010 [Epub ahead of print.]
Web of Science ®Google Scholar
SternbergCNSzczylikCLeeEA randomized, double-blind phase III study of pazopanib in treatment-naive and cytokine-pretreated patients with advanced renal cell carcinoma (RCC) [abstract]J Clin Oncol200927Suppl 155021
Web of Science ®Google Scholar
KasperBHohenbergerPPazopanib: a promising new agent in the treatment of soft tissue sarcomasFuture Oncol20117121373138322112314
PubMed Web of Science ®Google Scholar
Ray-CoquardIMaintenance therapy in the treatment of sarcomaClin Adv Hematol Oncol201191077377422252579
PubMedGoogle Scholar
ChawlaSPBlayJRay-CoquardILResults of the phase III, placebo-controlled trial (SUCCEED) evaluating the mTOR inhibitor ridaforolimus (R) as maintenance therapy in advanced sarcoma patients (pts) following clinical benefit from prior standard cytotoxic chemotherapy (CT) [abstract]J Clin Oncol20112910005
Web of Science ®Google Scholar
CassierPALabidi-GalySIHeudelPTherapeutic pipeline for soft-tissue sarcomaExpert Opin Pharmacother201112162479249121913865
PubMed Web of Science ®Google Scholar

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.

People also read
Recommended articles
Cited by

To cite this article:

Reference style: APA Chicago Harvard

Citation copied to clipboard

Reference styles above use APA (6th edition), Chicago (16th edition) & Harvard (10th edition)

Download citation

Download a citation file in RIS format that can be imported by citation management software including EndNote, ProCite, RefWorks and Reference Manager.

Choose format: RIS BibTex RefWorks Direct Export

Choose options: Citation Citation & abstract Citation & references

Pazopanib for the treatment of soft-tissue sarcoma

References

Information for

Open access

Opportunities

Help and information

Your download is now in progress and you may close this window

Login or register to access this feature

Pazopanib for the treatment of soft-tissue sarcoma

References

Related research

To cite this article:

Download citation

Information for

Open access

Opportunities

Help and information

Keep up to date